Repligen Corporation (RGEN) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Instruments & Supplies 산업에서 운영. 본사 소재지는 Waltham, MA, 미국. 현재 CEO는 Olivier Loeillot.
RGEN 을(를) 보유 IPO 날짜 1986-04-29, 1,778 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $7.38B.
Repligen Corporation is a global bioprocessing technology company that develops and commercializes systems and products for biological drug manufacturing. The company serves biopharmaceutical, life sciences, and diagnostics customers across North America, Europe, and Asia Pacific with a comprehensive portfolio including Protein A affinity chromatography resins, pre-packed chromatography columns, cell culture growth factors, filtration systems, and process analytics solutions. Its product lines—such as OPUS chromatography columns, XCell filtration systems, and SoloVPE spectroscopy platforms—support critical stages of biologic drug purification, concentration, and quality control. Repligen was founded in 1981 and is headquartered in Waltham, Massachusetts.
